23andMe

United States Direct-To-Consumer Genetic Testing Market Analysis Report 2023-2028: Personalized Genetic Testing Services Fuels Market Expansion - ResearchAndMarkets.com

Retrieved on: 
Friday, August 4, 2023
Biotechnology, Genetics, Health, Online, Sample, DTC, 23andMe, Pharmacy, Pharmacogenomics, Genetic testing, USD, Government, Competition, Pharmacotherapy, Market, Protein, Chromosome, Genetic disorder, Conditional sentence, Growth, Gene, Disease, Vaccine, Pharmaceutical industry

The "United States Direct-To-Consumer Genetic Testing Market - By Test Type, Technology, Sample, Distribution Channel, Region, Competition, Forecast and Opportunities, 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Direct-To-Consumer Genetic Testing Market - By Test Type, Technology, Sample, Distribution Channel, Region, Competition, Forecast and Opportunities, 2028" report has been added to ResearchAndMarkets.com's offering.
  • Through direct-to-consumer genetic testing, customers may be able to receive genetic tests with little or no participation from a third-party healthcare professional.
  • The high cost of DTC genetic testing services is limiting the growth of the US Direct-To-Consumer Genetic testing market.
  • Company Profiles: Detailed analysis of the major companies present in the United States Direct-To-Consumer Genetic Testing Market.

23andMe Releases New FDA-Cleared Genetic Report on Simvastatin, a Commonly Prescribed Statin

Retrieved on: 
Thursday, July 20, 2023
Lijun International Pharmaceutical (Holding) Co. Ltd., 23andMe, Genomic Health, Diet, Genetics, Stroke, Simvastatin, Pharmacogenomics, Cholesterol, Myopathy, Splenic infarction, Weakness, Prescription, Myalgia, Risk, Blood, SLCO1B1, Liver, FDA, Dietary supplement, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., July 20, 2023 (GLOBE NEWSWIRE) --  23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, released a new Simvastatin Medication Insight report as part of its 23andMe+ membership service that reports on a person's likelihood of experiencing side effects from this commonly prescribed statin drug.

Key Points: 
  • Simvastatin is a commonly prescribed statin drug used to lower cholesterol in the blood and reduce the risk of heart attacks, strokes, or other heart problems.
  • “But we have also known for some time that genetic differences play a major role in the effectiveness of many medicines.
  • The insight report provides clear information about whether an individual has an increased chance of experiencing side effects.
  • About 8 million people in the US were prescribed the statin simvastatin in 2020, amounting to about 36 million prescriptions, making it among the most prescribed medications in the United States.

23andMe Releases New Report Revealing Genetic Likelihood of Experiencing Panic Attacks

Retrieved on: 
Wednesday, June 21, 2023
Panic, Lijun International Pharmaceutical (Holding) Co. Ltd., Heart, Database, 23andMe, Depression, Life, Genetics, PRS, Anxiety, Hyperventilation, Harvard University, Science, Anxiety disorder, Report, Marker beacon, Post-traumatic stress disorder, Collection, SAN, Panic disorder, Panic attack, Coronary artery disease, Research, Mental health, PTSD, Nursing, Pharmaceutical industry, Self storage, Dietary supplement

The Panic Attacks Report, powered by 23andMe Research, adds to the collection of reports in the 23andMe service that focus on mental health, including reports also powered by 23andMe Research on depression and anxiety .

Key Points: 
  • The Panic Attacks Report, powered by 23andMe Research, adds to the collection of reports in the 23andMe service that focus on mental health, including reports also powered by 23andMe Research on depression and anxiety .
  • In some cases, if panic attacks occur more frequently and continue over time, they may be diagnosed as panic disorder, a type of anxiety disorder where panic attacks happen frequently.
  • 23andMe’s Panic Attacks Report is powered by data from people who have consented to participate in 23andMe Research.
  • 23andMe’s genetic health report on panic attacks can provide customers with helpful information on their estimated genetic likelihood of being diagnosed with the condition, but it is not a substitute for clinical diagnosis and treatment.

New 23andMe survey reveals nine out of ten physicians in the U.S. believe genetics play an important part of a patient’s complete health picture

Retrieved on: 
Tuesday, May 16, 2023
Medical genetics, Lijun International Pharmaceutical (Holding) Co. Ltd., Learning, DTC, 23andMe, DNA, Genomic Health, Education, Internal medicine, Health, Genetics, Privacy, Doctor of Philosophy, Education outreach, MD, Patient, Physician, Medscape, Genetic testing, Knowledge, Environment, Family, Pharmaceutical industry, Nursing

SUNNYVALE, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe) today announced that a new survey, which found that primary care physicians are more and more comfortable discussing genetic testing with their patients than they were two years ago, and that more than two-thirds of those physicians who’ve taken a test themselves would recommend testing for health purposes if a patient inquired.

Key Points: 
  • Based on this most recent survey, physicians’ attitudes seem to have evolved.
  • It can also help us diagnose diseases earlier and personalize management,” said Noura Abul-Husn, MD, PhD, Vice President of Genomic Health at 23andMe.
  • About 33 percent of doctors said they’d had patients wanting to discuss their genetic health risk information from a DTC genetic health test.
  • The survey is a follow-up to a 2018 survey and a 2020 survey on the same topic and on the same platform.

Reza Afkhami Joins 23andMe as Chief Corporate Development Officer

Retrieved on: 
Monday, May 8, 2023
Lijun International Pharmaceutical (Holding) Co. Ltd., 23andMe, GSK, University, Therapy, Genetics, Berkeley, Data collection, MBA, Georgetown University, Business administration, Acquisition, Patient, SAN, Drug discovery, Sickle cell disease, Afkhami, Ecosystem, Master of Business Administration, Health, Genome, Disease, Corporate development, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced the appointment of Reza Afkhami as its Chief Corporate Development Officer overseeing corporate development efforts across its therapeutics, research services and consumer groups.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced the appointment of Reza Afkhami as its Chief Corporate Development Officer overseeing corporate development efforts across its therapeutics, research services and consumer groups.
  • 23andMe Therapeutics has a pipeline of genetically validated discovery and clinical programs, which it intends to advance through collaborations with pharmaceutical companies.
  • Furthermore, 23andMe hopes to help the pharmaceutical industry improve its R&D productivity through genetically-driven target identification and portfolio prioritization.
  • Before joining 23andMe, Afkhami was Senior Vice President of Corporate Development and Strategy at Global Blood Therapeutics, a clinical-stage biopharmaceutical company
    focused on innovative therapies for the treatment of sickle cell disease.

ReCode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development

Retrieved on: 
Monday, April 17, 2023
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, 23andMe, GSK plc, Royal Brompton Hospital, Asthma, Drug development, MBBS, Therapy, SORT, Doctor of Philosophy, Bias, MBA, Recode, Inflammation, Messenger, Pulmonology, Novartis, Lane, Patient, Respiratory disease, Cystic fibrosis, Hospital, LNP, Biomarker, Pharmacology, Imperial College London, MRCP, Disease, Medical device, Pharmaceutical industry, Genentech

ReCode Therapeutics , a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today the appointment of John G. Matthews, MBBS, MRCP, Ph.D., as senior vice president of clinical development.

Key Points: 
  • ReCode Therapeutics , a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today the appointment of John G. Matthews, MBBS, MRCP, Ph.D., as senior vice president of clinical development.
  • Dr. Matthews will oversee clinical development planning and strategy.
  • “We are delighted to welcome Dr. Matthews to build and lead our clinical team,” said Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer, ReCode Therapeutics.
  • He spent the previous ten years at Genentech, a subsidiary of Roche, in leadership roles including senior group medical director.

Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness Program

Retrieved on: 
Tuesday, April 11, 2023
Lijun International Pharmaceutical (Holding) Co. Ltd., 23andMe, Genetics, Sickle cell trait, American Heart Association, National Science Foundation, SCFG, SCD, Health equity, MSM, Research, CVD, National Institutes of Health, Black, Bangladesh Technical Education Board, Morehouse School of Medicine, Student, National Football League Players Association, Apple Corps, Anti-transglutaminase antibodies, Hemoglobin subunit beta, SCT, Sickle cell disease, Genetic testing, Faculty, Health, FDA, HBB, African Americans, Mobile phone, Nursing, Pharmaceutical industry, UnitedHealth Group

ATLANTA and SOUTH SAN FRANCISCO, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Today, 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, Morehouse School of Medicine (MSM), and the Sickle Cell Foundation of Georgia (SCFG) announced the launch of a Sickle Cell Carrier Status Awareness program to help increase access to sickle cell carrier status information, raise awareness of sickle cell disease (SCD), and offer resources for individuals with sickle cell trait (SCT) and SCD.

Key Points: 
  • Program aims to increase access to information on sickle cell carrier status, and offer resources to individuals with sickle cell trait and sickle cell disease
    ATLANTA and SOUTH SAN FRANCISCO, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Today, 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, Morehouse School of Medicine (MSM), and the Sickle Cell Foundation of Georgia (SCFG) announced the launch of a Sickle Cell Carrier Status Awareness program to help increase access to sickle cell carrier status information, raise awareness of sickle cell disease (SCD), and offer resources for individuals with sickle cell trait (SCT) and SCD.
  • This includes genetic reports on several conditions that disproportionately affect the Black and African American community, including a Carrier Status report on sickle cell anemia*.
  • Program participants will also be offered counseling by the Sickle Cell Foundation of Georgia after receiving their 23andMe results.
  • 23andMe’s FDA-authorized Sickle Cell Anemia Carrier Status report tests for the HbS variant in the Hemoglobin Subunit Beta (HBB) gene, which is linked to sickle cell anemia and other forms of SCD.

23andMe Publishes Inaugural Environmental, Social and Governance Report

Retrieved on: 
Wednesday, March 29, 2023
Steel Azin Iranian Holding Co., 23andMe, San Francisco Bay Area, Genetics, Supplier Code of Conduct, Culture, Commitment, Research, Audit committee, Interface (computing), LEED, Ethics, Water, Biophysical environment, DEI, ESG, Entrepreneurship, Policy, LINK, Corruption, Platinum, Genome, Management, Renewable energy, Music, Woman

SOUTH SAN FRANCISCO, Calif., March 29, 2023 /PRNewswire/ -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today published its inaugural environmental, social and governance (ESG) report. The report outlines the Company's strategy and initiatives to ensure ethical management, promote a diverse and equitable culture, and implement sustainable business operations. The full report is available to view at LINK.

Key Points: 
  • The report outlines the Company's strategy and initiatives to ensure ethical management, promote a diverse and equitable culture, and implement sustainable business operations.
  • "We are proud to put out our first environmental, social and governance report.
  • We are committed to making our product, our community and our company diverse, inclusive and environmentally responsible," said Anne Wojcicki, CEO and Co-Founder, 23andMe.
  • 23andMe strives to ensure that everyone who uses its product receives meaningful value, and has an inclusive and accessible experience.

23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease

Retrieved on: 
Friday, March 24, 2023
Exercise, Lijun International Pharmaceutical (Holding) Co. Ltd., 23andMe, Obesity, Diet, Genetics, Stroke, Risk, SAN, Lipoprotein(a), Entrepreneurship, Health, Gene, Pharmaceutical industry, Novartis

High levels of Lp(a) are associated with increased risk of heart attack, stroke and other life threatening conditions.

Key Points: 
  • High levels of Lp(a) are associated with increased risk of heart attack, stroke and other life threatening conditions.
  • Roughly one in five people have high levels of Lp(a)1, which conveys a 2-4 times higher risk for heart disease2.
  • With support from Novartis, 23andMe is piloting a new program to educate its customers about the risks associated with high Lp(a).
  • “We are excited to work with Novartis to raise awareness of Lp(a) and the importance of understanding risks associated with high Lp(a).

Locke Bio Enables Emerging E-Commerce Brands to Sell Prescription Drugs Direct-to-Consumer

Retrieved on: 
Friday, March 17, 2023
Online, Workforce, DTC, 23andMe, Partnership, Series, Pharmacy, PT, Plasma protein binding, LegitScript, ET, Patient, The Next Phase, Online shopping, Pharmaceutical industry

LOS ANGELES, March 17, 2023 /PRNewswire/ -- Locke Bio, a digital health platform company, today announced a new offering targeted at emerging e-commerce and telehealth brand owners who want to expand their offering to include prescription drugs. The solution offers a streamlined platform experience at an affordable price point to enable smaller e-commerce companies to gain a foothold in this highly profitable market.

Key Points: 
  • LOS ANGELES, March 17, 2023 /PRNewswire/ -- Locke Bio , a digital health platform company, today announced a new offering targeted at emerging e-commerce and telehealth brand owners who want to expand their offering to include prescription drugs.
  • The new solution starts at $1,500 a month and gives e-commerce brands access to Locke Bio's white-labeled platform, including customized patient intake onboarding, e-commerce payment processing, and more.
  • Companies will also have access to Locke Bio's expansive U.S. and Canadian network of pharmacies and doctors.
  • Mailbox Meds , a men's sexual health e-commerce platform, is one of the clients already taking advantage of Locke Bio's new offering.